Year 2020 / Volume 112 / Number 9
Letter
Effective treatment of autoimmune hepatitis-primary biliary cholangitis overlap syndrome with obeticholic acid

737

DOI: 10.17235/reed.2020.6883/2020

Juan Diego Castro Limo, Marta Romero-Gutiérrez, Juan Ruiz Martín,

Abstract
There is no consensus treatment for patients with autoimmune hepatitis (AIH) – primary biliary cholangitis (PBC) overlap syndrome who are not responding to conventional therapy. We present a case of a 43-yr-old woman with AIH-PBC overlap syndrome treated with obeticholic acid (OCA). The patient showed a reduction in liver enzymes and no fibrosis progression during 15 months of follow up.
Share Button
New comment
Comments

03/05/2021 20:50:35
Research use


03/05/2021 20:50:00
Researchers


References
1. Zhang W, De D, Mohammed K, Munigala S, et al. New scoring classification for primary biliary cholangitis-autoinmmune hepatitis overlap syndrome. Hepatology Communications 2018; 2(3): 245-253.
2. European Association for the Study of the Liver. EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol 2017;67(1):145-172.
3. Martínez J, Aguilera L, Albillos A. Risk stratification and treatment of primary biliary cholangitis. Rev Esp Enferm Dig. 2019 Jan;111(1):63-70.
4. Nevens F, Andreone P, Mazzella G, et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med 2016; 375:631-643.
5. Corpechot C, Carrat F, Poujol-Robert A, et al. Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis. Hepatology 2012;56(1):198-208.
Related articles

Letter

Autoimmune hepatitis after SARS-C¬¬oV-2 vaccination

DOI: 10.17235/reed.2023.9579/2023

Letter

SARS-CoV-2 vaccine, a new autoimmune hepatitis trigger?

DOI: 10.17235/reed.2022.8820/2022

Editorial

Cases of liver disease lost in the health system: a call to action

DOI: 10.17235/reed.2021.8316/2021

Letter

Autoimmune hepatitis triggered by COVID-19

DOI: 10.17235/reed.2021.8045/2021

Review

Practical management of primary biliary cholangitis

DOI: 10.17235/reed.2021.8219/2021

Letter

Acute hepatitis due to olmesartan: an uncommon entity

DOI: 10.17235/reed.2020.7236/2020

Review

Risk stratification and treatment of primary biliary cholangitis

DOI: 10.17235/reed.2018.5662/2018

Letter to the Editor

Autoimmune hepatitis as a complication of common variable immunodeficiency

DOI: 10.17235/reed.2018.5280/2017

Case Report

The clinical extremes of autoimmune cholangitis

DOI: 10.17235/reed.2017.4167/2015

Citation tools
Castro Limo J, Romero-Gutiérrez M, Ruiz Martín J. Effective treatment of autoimmune hepatitis-primary biliary cholangitis overlap syndrome with obeticholic acid. 6883/2020


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 573 visits.
This article has been downloaded 315 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 15/01/2020

Accepted: 21/01/2020

Online First: 04/06/2020

Published: 10/09/2020

Article Online First time: 141 days

Article editing time: 239 days


Share
This article has been rated by 1 readers.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology